指南与共识胸部肿瘤

2021 USPSTF肺癌筛查推荐的成本效果评估

Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening.
指南 / 共识 · JAMA Oncol · 2021-01-01

该研究采用4个独立微模拟模型,比较2021与2013 USPSTF肺癌筛查推荐及6种替代策略的成本效果。2021推荐相对2013推荐具成本效果,平均ICER为72 564美元/QALY;但部分维持20包年且纳入戒烟≤25年者的替代策略成本效果更优。

要点

  • 2021 USPSTF推荐较2013推荐具成本效果,平均ICER为72 564美元/QALY。
  • 维持20包年但纳入戒烟≤25年者的替代策略成本效果更优。
  • 起始年龄55岁且戒烟≤25年的策略ICER为66 533美元/QALY。

核心结论

  • 2021 USPSTF肺癌筛查推荐具成本效果,但部分替代策略可能更优。

研究设计与样本

  • 采用4个独立开发的微模拟模型进行比较成本效果分析,模拟1960年美国出生队列,从45岁随访至死亡或90岁。

主要发现

  • 2021推荐相对2013推荐的平均ICER为72 564美元/QALY(4模型范围59 493–85 837)。
  • 2021推荐相对6种维持20包年的替代策略不具成本效果。
  • 起始年龄55岁且戒烟≤25年的策略平均ICER为66 533美元/QALY(范围55 693–80 539)。

关键数值与推荐

  • ICER低于100 000美元/QALY视为具成本效果。
  • 2021推荐将筛查起始年龄从55岁降至50岁,最小累积吸烟暴露从30包年降至20包年。
  • 替代策略维持20包年和筛查终止年龄80岁,变化起始年龄(50或55岁)及戒烟年限(≤15、≤20或≤25年)。

临床怎么用

  • 2021 USPSTF推荐可用于肺癌筛查且具成本效果。
  • 维持20包年但纳入戒烟≤25年者的策略可能更经济,值得进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The US Preventive Services Task Force (USPSTF) issued its 2021 recommendation on lung cancer screening, which lowered the starting age for screening from 55 to 50 years and the minimum cumulative smoking exposure from 30 to 20 pack-years relative to its 2013 recommendation. Although costs are expected to increase because of the expanded screening eligibility criteria, it is unknown whether the new guidelines for lung cancer screening are cost-effective. OBJECTIVE: To evaluate the cost-effectiveness of the 2021 USPSTF recommendation for lung cancer screening compared with the 2013 recommendation and to explore the cost-effectiveness of 6 alternative screening strategies that maintained a minimum cumulative smoking exposure of 20 pack-years and an ending age for screening of 80 years but varied the starting ages for screening (50 or 55 years) and the number of years since smoking cessation (≤15, ≤20, or ≤25). DESIGN, SETTING, AND PARTICIPANTS: A comparative cost-effectiveness analysis using 4 independently developed microsimulation models that shared common inputs to assess the population-level health benefits and costs of the 2021 recommended screening strategy and 6 alternative screening strategies compared with the 2013 recommended screening strategy. The models simulated a 1960 US birth cohort. Simulated individuals entered the study at age 45 years and were followed up until death or age 90 years, corresponding to a study period from January 1, 2005, to December 31, 2050. EXPOSURES: Low-dose computed tomography in lung cancer screening programs with a minimum cumulative smoking exposure of 20 pack-years. MAIN OUTCOMES AND MEASURES: Incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year (QALY) of the 2021 vs 2013 USPSTF lung cancer screening recommendations as well as 6 alternative screening strategies vs the 2013 USPSTF screening strategy. Strategies with a mean ICER lower than $100 000 per QALY were deemed cost-effective. RESULTS: The 2021 USPSTF recommendation was estimated to be cost-effective compared with the 2013 recommendation, with a mean ICER of $72 564 (range across 4 models, $59 493-$85 837) per QALY gained. The 2021 recommendation was not cost-effective compared with 6 alternative strategies that used the 20 pack-year criterion. Strategies associated with the most cost-effectiveness included those that expanded screening eligibility to include a greater number of former smokers who had not smoked for a longer duration (ie, ≤20 years and ≤25 years since smoking cessation vs ≤15 years since smoking cessation). In particular, the strategy that screened former smokers who quit within the past 25 years and began screening at age 55 years was associated with screening coverage closest to that of the 2021 USPSTF recommendation yet yielded greater cost-effectiveness, with a mean ICER of $66 533 (range across 4 models, $55 693-$80 539). CONCLUSIONS AND RELEVANCE: This economic evaluation found that the 2021 USPSTF recommendation for lung cancer screening was cost-effective; however, alternative screening strategies that maintained a minimum cumulative smoking exposure of 20 pack-years but included individuals who quit smoking within the past 25 years may be more cost-effective and warrant further evaluation.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Toumazis I, de Nijs K, Cao P, et al. Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening. JAMA Oncol. 2021. PMID: 34673885. doi:10.1001/jamaoncol.2021.4942

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。